Exabis Library
Welcome to the e-CCO Library!
P452: Safety and efficacy of infliximab biosimilar (Remsima©) in Crohn’s disease patients in clinical practice: results after 6 months of treatment
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P452: Silent anaemia predicts treatment change in patients with Crohn's disease in clinical remission
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P452: Tofacitinib Effectiveness and Safety as Therapy for Ulcerative Colitis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P453 Comparison of therapeutic effects between groups of thiopurine alone and combination of thiopurine with 5-ASA after remission introduced by oral tacrolimus for patients with severe ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P453: Efficacy of therapeutic drug monitoring of anti-TNF therapy in the control of patients with inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P453: Golimumab in real-world practice in patients with ulcerative colitis: 2-year interim results from a non-interventional trial in Germany
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P453: Insufficient vaccination and inadequate immunisation rates amongst Korean patients with inflammatory bowel diseases
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P453: Pre-operative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease: A systematic review and meta-analysis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P453: The significance of the concentration of antibodies to infliximab on the frequency of loss of response when alternating the original drug infliximab and its biosimilar in patients with ulcerative colitis.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P453: The use of immunosuppresants is associated with high treatment persistence rates for infliximab and adalimumab as first or second line anti-TNF therapy in patients with inflammatory bowel disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P453: Underutilisation of novel and alternative oral iron preparations may incur unnecessary cost in iron deficiency anaemia treatment in inflammatory bowel disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P454 Serum oncostatin M predicts mucosal healing in Crohn’s disease patients treated with infliximab
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P454: Can calcineurin inhibitors induce a durable remission that is maintained with vedolizumab in IBD?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P454: Combo-therapy in infliximab-resistant inflammatory bowel disease patients: data from a tertiary referral centre
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P454: Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P454: Evaluation of the nutritional care status in italian centers managing patients affected by inflammatory bowel disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P454: No increased postoperative risk of venous thromboembolism nor infectious complications after JAK inhibitor exposure in patients with ulcerative colitis undergoing colectomy
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P454: Prediction of endoscopic activity in patients with Crohn’s disease: systematic review and external validation of published prediction models
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P454: Treatment with biologics improves disability from Inflammatory Bowel Disease in therapy responders
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P455 Adherence to enteral nutrition therapy by adults with active Crohn’s disease is associated with conscientiousness personality trait
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM